Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the race to develop a COVID-19 vaccine, a lot of attention has been paid to the types of vaccines being developed and their progress through the various stages of clinical trial.

The Conversation logo

A lot less attention has been paid to what happens after a vaccine is approved by the regulators.

As recognised by a US scientific committee, governments need to start planning how they will distribute a vaccine efficiently and fairly, because, when a vaccine is approved, most countries won’t have enough doses to vaccinate everyone.

Read the full article on The Conversation website, written by Laurence Roope and Philip Clarke, Nuffield Department of Population Health

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.